Current Oncology, Free Full-Text

Triple-negative breast cancer (TNBC) has a worse prognosis and remains the most challenging breast cancer subtype to treat. This is largely related to the heterogeneity of this disease and the lack of reliable oncological targets. In this review, we discuss the current standard-of-care treatment options for metastatic TNBC, including recent advances with the use of immunotherapy, PARP inhibitors and antibody-drug conjugates. This review also explores new agents and novel combinations arising in the field for the treatment of advanced TNBC.

📆 Save the date - West Cancer Center & Research Institute

Cancer Facts & Figures 2023

Camp One Step provides free camp experience for kids with cancer

Current Oncology, Free Full-Text

Current Oncology, Free Full-Text

Journal of Clinical Oncology

Current Oncology 2022 - Browse Issues

Current Oncology 2023 - Browse Issues

Current Oncology An Open Access Journal from MDPI

Oncology Communication Training - Summer 2023

Current Oncology, Free Full-Text

Current Oncology, Free Full-Text, Skin Tone Construction Paper

First-line Atezolizumab Monotherapy Versus Single-agent, 43% OFF